Tumori Journal, 2015 and beyond: the right time for a change


Tumori 2015; 101(1): 1 - 1

Article Type: EDITORIAL



Ugo Pastorino

Article History

This article is available as full text PDF.

Download any of the following attachments:

More than a century has passed since the first issue of Tumori was published in 1911. The journal quickly established itself as a reference within the oncological community, publishing articles in Italian at first, and then adopting English as the reference language. Tumori was indeed amongst the first journals to be indexed in major databases including the National Library of Medicine’s Medline and ISI Current Contents, now available under the umbrella of Thomson Reuters Web of Science.

Whilst continuing to attract contributions from all over the world, the visibility of Tumori within the scientific community has been somewhat hampered by a publication model prioritizing print distribution over online availability.

2015 will see significant changes in the journal, starting from its title, to stress its nature of an international journal read by scientists and clinicians worldwide, with rapid online publication and Open Access capability upon request.

First of all, Tumori Journal will maintain its original nature, covering all branches of cancer science and clinical practice with a strong focus on prevention, translational medicine, and clinically relevant reports.

Most importantly, we want Tumori Journal to become a key reference for young investigators who are in the midst of their academic and/or clinical careers and wish to submit "as first authors" solid, methodologically sound investigations, not yet suitable for the most established and impacted journals. We are also inviting them to submit state-of-the-art reviews that will be able to summarize and critically analyze current evidence in all branches of oncology.

In addition, we want to stimulate and attract reports on large series of consecutive patients, that investigate the real impact of new techniques and treatments on day-to-day clinical practice. Our scope will be to implement the evidence from randomized clinical trials, with unselected evaluation of drugs and devices, and health technology assessments on the clinical, economic, and social consequences of cancer.

Last but not least, we welcome submissions of clinical trials protocols.

What we can promise to authors is a fair, rapid, and thorough peer-review process and, in case of acceptance, an ever increasing visibility of their contribution within the oncological community. To readers, we promise the publication of meaningful contributions that may improve basic and clinical oncology; to scientific societies, the affiliation to a 100+ years old journal, now fully equipped for 21st century, state-of-the-art publishing.

I welcome your comments, considerations, and suggestions and I look forward to meeting you as authors, reviewers, and readers of Tumori Journal.



  • Editor-in-Chief

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.